GB2345063B - Method - Google Patents
MethodInfo
- Publication number
- GB2345063B GB2345063B GB0006993A GB0006993A GB2345063B GB 2345063 B GB2345063 B GB 2345063B GB 0006993 A GB0006993 A GB 0006993A GB 0006993 A GB0006993 A GB 0006993A GB 2345063 B GB2345063 B GB 2345063B
- Authority
- GB
- United Kingdom
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15051—Methods of production or purification of viral material
- C12N2740/15052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6045—RNA rev transcr viruses
- C12N2810/6054—Retroviridae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Developmental Biology & Embryology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9720216.2A GB9720216D0 (en) | 1997-09-23 | 1997-09-23 | Delivery of therapeutic genes to haematopoietic stem cells |
GBGB9720465.5A GB9720465D0 (en) | 1997-09-25 | 1997-09-25 | Dual-virus vectors |
PCT/GB1998/002885 WO1999015684A2 (en) | 1997-09-23 | 1998-09-23 | Expression of genes in hematopoietic stem cells in hischaemic conditions |
Publications (3)
Publication Number | Publication Date |
---|---|
GB0006993D0 GB0006993D0 (en) | 2000-05-10 |
GB2345063A GB2345063A (en) | 2000-06-28 |
GB2345063B true GB2345063B (en) | 2002-07-24 |
Family
ID=26312300
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB0006993A Expired - Fee Related GB2345063B (en) | 1997-09-23 | 1998-09-23 | Method |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP1017838A2 (en) |
JP (1) | JP2001517453A (en) |
KR (1) | KR20010052076A (en) |
CN (1) | CN1303442A (en) |
AU (1) | AU747609B2 (en) |
CA (1) | CA2303663A1 (en) |
GB (1) | GB2345063B (en) |
IL (1) | IL134897A0 (en) |
NO (1) | NO20001487L (en) |
NZ (1) | NZ503318A (en) |
WO (1) | WO1999015684A2 (en) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002526083A (en) * | 1998-09-23 | 2002-08-20 | オックスフォード バイオメディカ(ユーケイ)リミテッド | Polynucleotide constructs and uses thereof |
US7148035B1 (en) | 1998-11-18 | 2006-12-12 | Oxford Biomedica (Uk) Limited | Polypeptide |
GB0400443D0 (en) | 2004-01-09 | 2004-02-11 | Oxford Biomedica Ltd | Cascade |
EP2042598A1 (en) | 1998-11-18 | 2009-04-01 | Oxford Biomedica (UK) Limited | 5T4 tumour-associated antigen for use in tumour immunotherapy |
GB9906615D0 (en) * | 1999-03-22 | 1999-05-19 | Oxford Biomedica Ltd | Vector |
WO2001066150A2 (en) * | 2000-03-07 | 2001-09-13 | St. Jude Children's Research Hospital | Highly efficient gene transfer into human repopulating stem cel ls by rd114 pseudotyped retroviral vector particles |
US6849454B2 (en) | 2000-03-07 | 2005-02-01 | St. Jude Children's Research Hospital | Highly efficient gene transfer into human repopulating stem cells by RD114 pseudotyped retroviral vector particles |
GB0009760D0 (en) | 2000-04-19 | 2000-06-07 | Oxford Biomedica Ltd | Method |
GB0024550D0 (en) * | 2000-10-06 | 2000-11-22 | Oxford Biomedica Ltd | |
US6573092B1 (en) | 2000-10-10 | 2003-06-03 | Genvec, Inc. | Method of preparing a eukaryotic viral vector |
GB0203419D0 (en) | 2002-02-13 | 2002-04-03 | Oxford Biomedica Ltd | Peptide |
GB0203420D0 (en) | 2002-02-13 | 2002-04-03 | Oxford Biomedica Ltd | Peptide |
CA2965865C (en) | 2002-07-18 | 2021-10-19 | Merus N.V. | Recombinant production of mixtures of antibodies |
CA2527694C (en) | 2003-05-30 | 2015-07-14 | Hendricus Renerus Jacobus Mattheus Hoogenboom | Fab library for the preparation of anti vegf and anti rabies virus fabs |
US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
JP4572320B2 (en) * | 2004-02-23 | 2010-11-04 | 財団法人大阪産業振興機構 | Recombinant human cell and method for evaluating at least one of induction of drug metabolizing enzyme and drug metabolism using the recombinant human cell |
EP2045268B1 (en) | 2005-05-13 | 2011-09-21 | Oxford BioMedica (UK) Limited | Mhc class I and II peptide antigens derived from tumour antigen 5t4 |
EP2079832A4 (en) | 2006-05-17 | 2010-08-04 | Cognate Therapeutics Inc | Isolation and purification of hematopoietic stem cells from post-liposuction lipoaspirates |
MX360110B (en) | 2012-04-20 | 2018-10-23 | Merus Nv | Methods and means for the production of ig-like molecules. |
JP7007273B2 (en) | 2015-12-22 | 2022-01-24 | アンセルム(アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル) | Improved complex double-recombinant AAV vector system for gene therapy |
CN113699146A (en) * | 2020-05-22 | 2021-11-26 | 深圳市深研生物科技有限公司 | Promoter element, retroviral genome transcription cassette comprising the same, and vector |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993002556A1 (en) * | 1991-07-26 | 1993-02-18 | University Of Rochester | Cancer therapy utilizing malignant cells |
WO1995006120A1 (en) * | 1993-08-25 | 1995-03-02 | Rhone-Poulenc Rorer S.A. | Recombinant cells from the monocyte-macrophage cell line for gene therapy |
WO1995021927A2 (en) * | 1994-02-15 | 1995-08-17 | Isis Innovation Limited | Targeting gene therapy |
WO1995029704A1 (en) * | 1994-04-28 | 1995-11-09 | Scott Freeman | Cell lines obtained by in vivo migration and by fusion with autoimmune cells |
WO1996020276A1 (en) * | 1994-12-23 | 1996-07-04 | Sri International | Tissue specific hypoxia regulated therapeutic constructs |
WO1998015294A1 (en) * | 1996-10-09 | 1998-04-16 | Oxford Biomedica (Uk) Limited | Mononuclear phagocytes in therapeutic drug delivery |
-
1998
- 1998-09-23 GB GB0006993A patent/GB2345063B/en not_active Expired - Fee Related
- 1998-09-23 IL IL13489798A patent/IL134897A0/en unknown
- 1998-09-23 CA CA002303663A patent/CA2303663A1/en not_active Abandoned
- 1998-09-23 NZ NZ503318A patent/NZ503318A/en unknown
- 1998-09-23 WO PCT/GB1998/002885 patent/WO1999015684A2/en not_active Application Discontinuation
- 1998-09-23 EP EP98946556A patent/EP1017838A2/en not_active Withdrawn
- 1998-09-23 CN CN98811427A patent/CN1303442A/en active Pending
- 1998-09-23 AU AU93562/98A patent/AU747609B2/en not_active Ceased
- 1998-09-23 KR KR1020007003066A patent/KR20010052076A/en not_active Application Discontinuation
- 1998-09-23 JP JP2000512973A patent/JP2001517453A/en active Pending
-
2000
- 2000-03-22 NO NO20001487A patent/NO20001487L/en unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993002556A1 (en) * | 1991-07-26 | 1993-02-18 | University Of Rochester | Cancer therapy utilizing malignant cells |
WO1995006120A1 (en) * | 1993-08-25 | 1995-03-02 | Rhone-Poulenc Rorer S.A. | Recombinant cells from the monocyte-macrophage cell line for gene therapy |
WO1995021927A2 (en) * | 1994-02-15 | 1995-08-17 | Isis Innovation Limited | Targeting gene therapy |
WO1995029704A1 (en) * | 1994-04-28 | 1995-11-09 | Scott Freeman | Cell lines obtained by in vivo migration and by fusion with autoimmune cells |
WO1996020276A1 (en) * | 1994-12-23 | 1996-07-04 | Sri International | Tissue specific hypoxia regulated therapeutic constructs |
WO1998015294A1 (en) * | 1996-10-09 | 1998-04-16 | Oxford Biomedica (Uk) Limited | Mononuclear phagocytes in therapeutic drug delivery |
Non-Patent Citations (5)
Title |
---|
Annals N Y Acad. Sci. "Gene Therapy for Neoplastic Diseases"1994. Boris-Lawrie K et.al. pages 59-71 * |
Annals N Y Acad. Sci. "Gene Therapy for Neoplastic Diseases"1994. Hwu P & Rosenberg S A pages 188-99 * |
Cloning Vectors (Laboratory Manual) Elsvier Amsterdam 1985. Pouwels P H et.al. pages VIII-1-VIII-25 * |
Faseb J Vol. 11 (11) 1997. Bilbao G et.al. pages 624-634 * |
Path. Soc. Gt Britain & Ireland Vol. 182 1997. Lewis J et. al. page 1A * |
Also Published As
Publication number | Publication date |
---|---|
JP2001517453A (en) | 2001-10-09 |
WO1999015684A2 (en) | 1999-04-01 |
IL134897A0 (en) | 2001-05-20 |
EP1017838A2 (en) | 2000-07-12 |
CA2303663A1 (en) | 1999-04-01 |
WO1999015684A9 (en) | 1999-09-16 |
GB2345063A (en) | 2000-06-28 |
AU9356298A (en) | 1999-04-12 |
KR20010052076A (en) | 2001-06-25 |
AU747609B2 (en) | 2002-05-16 |
NZ503318A (en) | 2001-11-30 |
GB0006993D0 (en) | 2000-05-10 |
NO20001487L (en) | 2000-05-23 |
WO1999015684A8 (en) | 1999-08-12 |
WO1999015684A3 (en) | 1999-06-10 |
CN1303442A (en) | 2001-07-11 |
NO20001487D0 (en) | 2000-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB9717766D0 (en) | Methods | |
HUP0000911A3 (en) | Refuse-treatment method | |
GB2345063B (en) | Method | |
GB9721603D0 (en) | Method | |
GB9706282D0 (en) | Method | |
GB9702592D0 (en) | Selection method | |
PL334701A1 (en) | Novel method | |
GB9700320D0 (en) | Method | |
GB9708918D0 (en) | Methods | |
GB9707744D0 (en) | Method | |
ZA9810471B (en) | New method | |
GB9707742D0 (en) | Methods | |
GB9718591D0 (en) | Methods | |
GB9717652D0 (en) | Method | |
PL341657A1 (en) | Deparaffining method | |
GB9605482D0 (en) | Method | |
GB9709811D0 (en) | Method | |
GB9725462D0 (en) | Novel method | |
GB9723920D0 (en) | Method | |
GB9712984D0 (en) | Method | |
GB9719611D0 (en) | Method | |
GB9719059D0 (en) | Method | |
GB9718593D0 (en) | Method | |
GB9714760D0 (en) | Method | |
GB9724590D0 (en) | Method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PCNP | Patent ceased through non-payment of renewal fee |
Effective date: 20090923 |